Compare Abbott India with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs GLENMARK PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA GLENMARK PHARMA ABBOTT INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 52.5 18.6 281.6% View Chart
P/BV x 17.0 3.1 554.0% View Chart
Dividend Yield % 0.4 0.3 123.3%  

Financials

 ABBOTT INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
GLENMARK PHARMA
Mar-19
ABBOTT INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs8,834712 1,241.4%   
Low Rs5,458484 1,128.5%   
Sales per share (Unadj.) Rs1,731.1349.6 495.1%  
Earnings per share (Unadj.) Rs211.932.8 646.5%  
Cash flow per share (Unadj.) Rs219.944.3 496.0%  
Dividends per share (Unadj.) Rs65.002.00 3,250.0%  
Dividend yield (eoy) %0.90.3 271.8%  
Book value per share (Unadj.) Rs945.2198.6 475.8%  
Shares outstanding (eoy) m21.25282.17 7.5%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x4.11.7 241.5%   
Avg P/E ratio x33.718.2 185.0%  
P/CF ratio (eoy) x32.513.5 241.1%  
Price / Book Value ratio x7.63.0 251.3%  
Dividend payout %30.76.1 502.7%   
Avg Mkt Cap Rs m151,848168,625 90.1%   
No. of employees `0003.512.0 29.0%   
Total wages/salary Rs m4,35620,561 21.2%   
Avg. sales/employee Rs Th10,555.58,196.0 128.8%   
Avg. wages/employee Rs Th1,249.91,708.1 73.2%   
Avg. net profit/employee Rs Th1,292.2768.5 168.2%   
INCOME DATA
Net Sales Rs m36,78698,655 37.3%  
Other income Rs m1,1332,081 54.4%   
Total revenues Rs m37,919100,736 37.6%   
Gross profit Rs m6,04715,858 38.1%  
Depreciation Rs m1693,259 5.2%   
Interest Rs m233,346 0.7%   
Profit before tax Rs m6,98911,335 61.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m2,4853,756 66.2%   
Profit after tax Rs m4,5039,250 48.7%  
Gross profit margin %16.416.1 102.3%  
Effective tax rate %35.633.1 107.3%   
Net profit margin %12.29.4 130.6%  
BALANCE SHEET DATA
Current assets Rs m27,61066,968 41.2%   
Current liabilities Rs m8,56940,211 21.3%   
Net working cap to sales %51.827.1 190.8%  
Current ratio x3.21.7 193.5%  
Inventory Days Days6083 72.3%  
Debtors Days Days2781 33.7%  
Net fixed assets Rs m1,05733,322 3.2%   
Share capital Rs m213282 75.3%   
"Free" reserves Rs m19,87355,770 35.6%   
Net worth Rs m20,08656,052 35.8%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m29,409132,888 22.1%  
Interest coverage x311.64.4 7,101.9%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.7 168.5%   
Return on assets %15.49.5 162.4%  
Return on equity %22.416.5 135.9%  
Return on capital %34.917.8 195.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36962,998 0.6%   
Fx outflow Rs m4,91822,859 21.5%   
Net fx Rs m-4,54940,140 -11.3%   
CASH FLOW
From Operations Rs m4,99113,242 37.7%  
From Investments Rs m-2,570-6,990 36.8%  
From Financial Activity Rs m-1,428-7,387 19.3%  
Net Cashflow Rs m993-2,971 -33.4%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 6.9 114.5%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.5 162.9%  
Shareholders   18,270 56,727 32.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  WOCKHARDT  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Zoomed 613 Points Today(Closing)

Indian share markets extended gains as the session progressed and ended on a strong note.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


May 18, 2021 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS